In the non-HPV E6/E7+ tumors, EMT6 and MC38, the combination of NHS-IL12 and bintrafusp alfa synergized with antitumor efficacy and increased tumor-infiltrating CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.